Atara Biotherapeutics, Inc. (0HIY.L)
USD 7.88
(1.39%)
USD 7.88
(1.39%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 275.69 Million USD | -21.83% |
| 2022 | 344.08 Million USD | -4.63% |
| 2021 | 360.8 Million USD | 16.74% |
| 2020 | 309.05 Million USD | 4.52% |
| 2019 | 295.68 Million USD | 24.7% |
| 2018 | 237.11 Million USD | 95.1% |
| 2017 | 121.53 Million USD | 49.59% |
| 2016 | 81.24 Million USD | 39.0% |
| 2015 | 58.44 Million USD | 107.59% |
| 2014 | 28.15 Million USD | 226.83% |
| 2013 | 8.61 Million USD | -29.84% |
| 2012 | 12.27 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 41.88 Million USD | -18.55% |
| 2024 Q1 | 51.86 Million USD | -4.6% |
| 2023 Q1 | 76.02 Million USD | 0.35% |
| 2023 FY | 268.96 Million USD | -21.83% |
| 2023 Q4 | 54.36 Million USD | -21.36% |
| 2023 Q3 | 69.13 Million USD | -0.49% |
| 2023 Q2 | 69.47 Million USD | -8.62% |
| 2022 Q4 | 75.76 Million USD | -14.95% |
| 2022 Q1 | 95.53 Million USD | -5.37% |
| 2022 Q2 | 83.71 Million USD | -12.38% |
| 2022 FY | 344.08 Million USD | -4.63% |
| 2022 Q3 | 89.08 Million USD | 6.41% |
| 2021 Q3 | 90.18 Million USD | 2.63% |
| 2021 Q4 | 100.95 Million USD | 11.94% |
| 2021 Q1 | 81.79 Million USD | 0.12% |
| 2021 FY | 360.8 Million USD | 16.74% |
| 2021 Q2 | 87.87 Million USD | 7.43% |
| 2020 Q4 | 81.69 Million USD | 9.36% |
| 2020 Q1 | 74.69 Million USD | -6.28% |
| 2020 Q2 | 77.95 Million USD | 4.36% |
| 2020 Q3 | 74.7 Million USD | -4.16% |
| 2020 FY | 309.05 Million USD | 4.52% |
| 2019 Q2 | 75.53 Million USD | 11.26% |
| 2019 Q1 | 67.89 Million USD | -17.02% |
| 2019 FY | 295.68 Million USD | 24.7% |
| 2019 Q4 | 79.69 Million USD | 9.84% |
| 2019 Q3 | 72.55 Million USD | -3.94% |
| 2018 Q3 | 60.22 Million USD | 14.44% |
| 2018 Q1 | 42.45 Million USD | 18.57% |
| 2018 FY | 237.11 Million USD | 95.1% |
| 2018 Q4 | 81.81 Million USD | 35.86% |
| 2018 Q2 | 52.62 Million USD | 23.96% |
| 2017 Q1 | 26.16 Million USD | 39.5% |
| 2017 FY | 121.53 Million USD | 49.59% |
| 2017 Q4 | 35.8 Million USD | 13.08% |
| 2017 Q3 | 31.66 Million USD | 13.44% |
| 2017 Q2 | 27.9 Million USD | 6.68% |
| 2016 Q2 | 19.48 Million USD | 14.21% |
| 2016 Q1 | 17.06 Million USD | -35.06% |
| 2016 FY | 81.24 Million USD | 39.0% |
| 2016 Q4 | 18.75 Million USD | -27.71% |
| 2016 Q3 | 25.94 Million USD | 33.14% |
| 2015 FY | 58.44 Million USD | 107.59% |
| 2015 Q2 | 10.6 Million USD | 13.93% |
| 2015 Q1 | 9.31 Million USD | -12.13% |
| 2015 Q4 | 26.27 Million USD | 114.29% |
| 2015 Q3 | 12.25 Million USD | 15.56% |
| 2014 Q2 | 4.53 Million USD | -35.93% |
| 2014 Q4 | 10.59 Million USD | 78.11% |
| 2014 FY | 28.15 Million USD | 226.83% |
| 2014 Q3 | 5.94 Million USD | 31.21% |
| 2014 Q1 | 7.07 Million USD | 107.11% |
| 2013 Q1 | 1.28 Million USD | 0.0% |
| 2013 Q3 | 2.55 Million USD | 87.51% |
| 2013 Q4 | 3.41 Million USD | 33.89% |
| 2013 FY | 8.61 Million USD | -29.84% |
| 2013 Q2 | 1.36 Million USD | 5.83% |
| 2012 FY | 12.27 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | 3.295% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -468.416% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -2170.76% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 32.561% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -93.519% |
| Imunon, Inc. | 21.03 Million USD | -1210.924% |
| Dynavax Technologies Corporation | 219.14 Million USD | -25.804% |
| Editas Medicine, Inc. | 247.3 Million USD | -11.479% |
| FibroGen, Inc. | 398.11 Million USD | 30.75% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 38.87% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -604.143% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 82.731% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 79.741% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 47.885% |
| Verastem, Inc. | 92.08 Million USD | -199.393% |
| Zoetis Inc. | 2.76 Billion USD | 90.029% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 94.226% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -20.558% |
| Homology Medicines, Inc. | 9.87 Million USD | -2691.828% |
| Nektar Therapeutics | 190.9 Million USD | -44.415% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -173.432% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -517.219% |
| Perrigo Company plc | 1.52 Billion USD | 81.963% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -1.396% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.321% |
| Illumina, Inc. | 3.81 Billion USD | 92.77% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 97.311% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 86.571% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -128.493% |
| Waters Corporation | 943.51 Million USD | 70.78% |
| Biogen Inc. | 5.2 Billion USD | 94.703% |
| Evolus, Inc. | 189.75 Million USD | -45.286% |
| Adicet Bio, Inc. | 152.03 Million USD | -81.332% |
| bluebird bio, Inc. | 240.23 Million USD | -14.761% |
| Geron Corporation | 70.44 Million USD | -291.381% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 84.684% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 35.533% |
| Myriad Genetics, Inc. | 600.1 Million USD | 54.059% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 50.016% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 74.693% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1882.028% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 84.213% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 90.207% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 86.965% |
| OPKO Health, Inc. | 574.68 Million USD | 52.027% |
| Exelixis, Inc. | 1.58 Billion USD | 82.626% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 25.208% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -394.463% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 42.125% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 64.636% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 7.893% |
| Blueprint Medicines Corporation | 722.86 Million USD | 61.861% |
| Insmed Incorporated | 949.26 Million USD | 70.957% |
| TG Therapeutics, Inc. | 198.47 Million USD | -38.906% |
| Incyte Corporation | 1.19 Billion USD | 76.842% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 73.593% |